Heyman Richard A. sold $4K of ORIC (indirect holdings)
Heyman Richard A. sold 300 indirectly-held shares of Oric Pharmaceuticals, Inc. (ORIC) at $12.00 on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale of 300 shares at $12.00/share on 2026-07-06, with holdings after the transaction reported as 212,772 shares.
Market read
Traders may note insider selling activity, but the 10b5-1 structure and small size limit decision usefulness.
What to watch
The filing does not disclose any change in company outlook, clinical progress, or financing; without those, the trading signal is weak.
Background
This is an SEC Form 4 insider transaction disclosure for Oric Pharmaceuticals, Inc. (ORIC).
Ticker impact
Oric Pharmaceuticals director Heyman Richard A. sold 300 shares on 2026-07-06 at $12.00/share under a 10b5-1 plan, per Form 4.
Low near-term impact; any reaction is likely muted unless paired with other disclosures.
The filing is a small, pre-arranged open-market sale by a director, with no new operational or financial guidance disclosed.
Market effects
No clear sector read-through from a single small 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification or tax planning rather than bearish fundamentals.
Key entities
- issuerOric Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHeyman Richard A.
Director who executed the 10b5-1 open-market sale.